Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Missouri
Clinical trial register · United States · industry-sponsored

Clinical Trials in Missouri, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Missouri

18 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Novartis Pharmaceuticals
Phase 2
164
Arkansas, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri, Montana
2026-08-04
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993Schizophrenia
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
Remibrutinib in Real-world Clinical Practice
NCT07358364Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
3,280
Missouri
2026-02-02
Recruiting
Remibrutinib in Real-world Clinical Practice - a US Sub-study
NCT07358780Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
505
Missouri
2026-02-02
Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
DrugVHB937
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
55
Florida, Georgia, Kentucky, Missouri, New Jersey, Ohio, Pennsylvania
2022-07-13
Recruiting
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
NCT04939610Solid Tumor
Novartis Pharmaceuticals
Phase 1/2
222
Alabama, California, Florida, Illinois, Iowa, Michigan, Minnesota, Missouri
2021-07-30
Active, closed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
469
Colorado, Florida, Louisiana, Massachusetts, Missouri, Nebraska, New York, North Carolina
2021-06-15
Active, closed
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
Phase 2
206
California, Colorado, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas
2021-04-19
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/missouri

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Missouri that also match the filters currently applied.

How many clinical trials are recruiting in Missouri?

14 of the 18 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Missouri), 18 studies
PhaseStudiesRecruitingShare
Phase 27538.9%
Observational3316.7%
Phase 1/23216.7%
Phase 33216.7%
Phase 1115.6%
Phase 2/3115.6%

Most active sponsors

Lead sponsors with the most studies (Missouri)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals1814
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.